110
Participants
Start Date
August 9, 2024
Primary Completion Date
February 8, 2027
Study Completion Date
February 8, 2028
Venetoclax
Venetoclax tablets will be administered as per the schedule specified in the arm.
cBTKi Monotherapy
Commercially available cBTKi (ibrutinib or acalabrutinib, or zanubrutinib) will be administered in accordance with its prescribing label.
WITHDRAWN
University Cancer & Blood Center, LLC, Athens
RECRUITING
Tennessee Oncology - Midtown, Nashville
RECRUITING
Tennessee Oncology, PLLC - Chattanooga, Chattanooga
RECRUITING
Ohio State University, Columbus
RECRUITING
Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne
RECRUITING
Medical College of Wisconsin, Milwaukee
RECRUITING
Nebraska Cancer Specialists St Francis - Grand Island, Grand Island
RECRUITING
Highlands Oncology Group, Springdale
RECRUITING
Texas Oncology- Northeast Texas, Tyler
RECRUITING
MD Anderson Cancer Center, Houston
COMPLETED
San Juan Oncology Associates, PC, Farmington
RECRUITING
Rocky Mountain Cancer Centers (Aurora) - USOR, Aurora
RECRUITING
Cancer Specialists of North Florida, Jacksonville
RECRUITING
Mission Blood and Cancer - MercyOne Cancer Center, Des Moines
RECRUITING
American Oncology Partners of Maryland, PA, Bethesda
RECRUITING
Dana-Farber Cancer Institute - Hematologic Oncology Treatment Center, Boston
RECRUITING
Nebraska Cancer Specialists, Omaha
RECRUITING
Astera Cancer Care East Brunswick, East Brunswick
RECRUITING
Oncology Hematology Care Inc - Cincinnati - USOR, Cincinnati
RECRUITING
Oncology Associates of Oregon, P.C., Eugene
RECRUITING
Asante Rogue Regional Medical Center, Medford
Lead Sponsor
Genentech, Inc.
INDUSTRY